SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.
Last trade$13.19
Day change-$1.86 (-12.36%)
Day range$13.01 – $16.86
Volume86,425
Market cap$98M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$98.05M
Price / earnings
—
Price / book
1.76×
Price / sales
0.34×
EV / sales
0.79×
EV / EBITDA
8.13×
Profitability
Earnings per share
-$2.81
Return on assets
-4.7%
Return on equity
-32.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.36×
Current ratio
2.89×
Quick ratio
2.22×
Cash ratio
1.61×
Cash flow
Price / cash flow
4.16×
Price / free cash flow
4.32×
Free cash flow
$22.69M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SKIN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$69.17M
$72.11M
$64.91M
$82.37M
$70.66M
$78.19M
$69.58M
$83.5M
Cost of revenue
$22.02M
$22.78M
$20.47M
$29.33M
$25.02M
$29.08M
$21M
$31.15M
Gross profit
$47.15M
$49.34M
$44.44M
$53.04M
$45.63M
$49.11M
$48.58M
$52.35M
Selling, general and administrative
$40.51M
$44.36M
$45.14M
$51.2M
$50.18M
$50.56M
$59.61M
$58.28M
Research and development
$1.66M
$1.41M
$1.1M
$1.68M
$1.7M
$1.25M
$998K
$1.22M
Total operating expenses
$42.17M
$45.77M
$46.24M
$52.88M
$51.88M
$51.81M
$60.6M
$59.5M
Operating income
$4.98M
$3.57M
-$1.8M
$162K
-$6.24M
-$2.7M
-$12.02M
-$7.16M
Interest expense
-$6.27M
-$6.3M
-$6.35M
-$6.37M
-$6.31M
-$4.14M
-$2.5M
-$2.46M
Income before taxes
-$108K
-$1.46M
-$6.81M
-$4.81M
-$10.65M
$18.72M
-$9.2M
-$11.72M
Income taxes
$780K
$1.21M
-$184K
$3.3M
$386K
-$993K
$892K
-$1.39M
Net income
-$888K
-$2.67M
-$6.63M
-$8.1M
-$11.03M
$19.71M
-$10.1M
-$10.33M
Net income attributable to common shareholders
-$888K
-$2.67M
-$6.63M
-$8.1M
-$11.03M
$19.71M
-$10.1M
-$10.33M
EBITDA
$10.25M
$8.84M
$3.54M
$5.51M
$2.19M
$2.7M
-$5.86M
-$598K
Basic earnings per share
-$0.14
-$0.40
-$1.00
-$1.27
-$1.74
$3.20
-$1.60
-$1.66
Diluted earnings per share
-$0.14
-$0.40
-$1.00
-$1.07
-$1.74
$0.60
-$1.60
-$1.30
Recent news
Company coverage with links to the original publishers.
SkinHealth Systems Inc. (SKIN) reported a Q3 loss of $0.14 per share, significantly beating the consensus estimate of a $1.32 loss, representing an 89.39% earnings surprise. Revenue reached $69.2 million, surpassing estimates by 3%. However, the stock has declined 60.3% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
SkinHealth Systems Inc. reported Q3 2026 revenue of $69.2 million, down 2.1% year-over-year but beating consensus estimates by 3%. The company posted an EPS of -$0.14, a significant improvement from -$1.80 a year ago and beating estimates by 89.39%. While consumables sales grew 1.2% and Americas revenue increased 1.2%, EMEA revenue declined 11.8% and delivery systems sales fell 9.6%. The stock has underperformed the broader market, declining 6.3% over the past month.
SkinHealth Systems Inc. (SKIN) shares jumped 9% following completion of a 1-for-20 reverse stock split on October 14, 2026, which helped the company regain compliance with Nasdaq's minimum bid price requirement. However, the company faces significant headwinds with expected quarterly losses of $1.35 per share (down 1400% year-over-year) and revenues projected to decline 5% to $67.18 million. With no recent changes in earnings estimate revisions and a Zacks Rank #3 (Hold) rating, analysts question whether the recent rally can sustain.
SkinHealth Systems announced the launch of HydraClear Treatment Booster, a triple-acid formula designed to clarify and balance blemish-prone skin. Clinical trials showed a 38% mean reduction in total blemishes after four treatments, with 81% of participants showing fewer visible blemishes. The product will be integrated into Deluxe and Platinum Hydrafacial treatments.
SkinHealth Systems (Nasdaq: SKIN) announced the European launch of SkinStylus® SteriLock® MicroSystem, a professional micro- and nano-needling device, now available in the UK, Ireland, Germany, France, Spain, and Portugal. The expansion leverages the company's established Hydrafacial distribution network and aims to offer complementary aesthetic solutions to practitioners across the region.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.